Skip to main navigation Skip to search Skip to main content

ExPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants with Parkinson's Disease

Project: Research

Project Details

StatusActive
Effective start/end date09/19/25 → 05/1/30

Funding

  • BlueRock Therapeutics Limited Partnership: $30,434.16